专题：Cancer therapeutics and mechanisms

This cluster of papers focuses on the structure, function, inhibition, and genetic variants of DNA topoisomerases, particularly their roles in chemotherapy, the mechanism of action of specific inhibitors such as irinotecan and quinolones, and their impact on genomic stability. The papers also explore the potential use of genetic variants in predicting drug toxicity and treatment outcomes.
最新文献
A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers

article Full Text OpenAlex

Understanding and overcoming multidrug resistance in cancer

review Full Text OpenAlex

Search for specific Inhibitors targeting type IA topoisomerases.

review Full Text OpenAlex

Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.

article Full Text OpenAlex

Optimal dosing and duration of linezolid for the treatment of multidrug-resistant and rifampicin-resistant tuberculosis: An individual patient data meta-analysis

review Full Text OpenAlex

Multistage Molecular Simulations, Design, Synthesis, and Anticonvulsant Evaluation of 2-(Isoindolin-2-yl) Esters of Aromatic Amino Acids Targeting GABAA Receptors via π–π Stacking

preprint Full Text OpenAlex

Antineoplastic effects of erufosine in combination with oxaliplatin in colorectal cancer

article Full Text OpenAlex

DPD Ultra‐Rapid Metabolizer Status and Efficacy of 5‐Fluorouracil Treatment: A Real‐World Study

article Full Text OpenAlex

Targeting drug-resistant tuberculosis: Thioacetamide-substituted benzothiazoles as bactericidal agents inhibiting type II NADH dehydrogenase

article Full Text OpenAlex

Drug Resistance Predictions Based on a Directed Flag Transformer

article Full Text OpenAlex

近5年高被引文献
Small-cell lung cancer

review Full Text OpenAlex 1114 FWCI32.298

Molecular mechanisms of antibiotic resistance revisited

review Full Text OpenAlex 847 FWCI20.408

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

article Full Text OpenAlex 637 FWCI51.548

Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation

article Full Text OpenAlex 408 FWCI27.086

Overcoming therapy resistance in EGFR-mutant lung cancer

review Full Text OpenAlex 401 FWCI14.211

Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches

review Full Text OpenAlex 394 FWCI16.241

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

review Full Text OpenAlex 360 FWCI21.177

Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group

article Full Text OpenAlex 355 FWCI34.843

Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine

review Full Text OpenAlex 334 FWCI16.835

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer

article Full Text OpenAlex 329 FWCI44.775